Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
ENRIGHT PATRICK G
   2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [JAZZ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220		 3. Date of Earliest Transaction (Month/Day/Year)
02/28/2014
(Street)

MENLO PARK, CA 94025		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 02/28/2014   X   929,243 A (1) $ 4 929,243 (2) I By Longitude Venture Partners, L.P. (3)
Ordinary Shares 02/28/2014   X   18,624 A (1) $ 4 18,624 (2) I By Longitude Capital Associates, L.P. (3)
Ordinary Shares 02/28/2014   S   686 D $ 165.94 928,557 I By Longitude Venture Partners, L.P. (3)
Ordinary Shares 02/28/2014   S   14 D $ 165.94 18,610 I By Longitude Capital Associates, L.P. (3)
Ordinary Shares 02/28/2014   S   28 D $ 164.5 928,529 I By Longitude Venture Partners, L.P. (3)
Ordinary Shares 02/28/2014   S   1 D $ 164.5 18,609 I By Longitude Capital Associates, L.P. (3)
Ordinary Shares 02/28/2014   S   3,645 D $ 162.9373 (4) 924,884 I By Longitude Venture Partners, L.P. (3)
Ordinary Shares 02/28/2014   S   71 D $ 162.9396 (5) 18,538 I By Longitude Capital Associates, L.P. (3)
Ordinary Shares 02/28/2014   S   39,241 D $ 161.9339 (6) 885,643 I By Longitude Venture Partners, L.P. (3)
Ordinary Shares 02/28/2014   S   787 D $ 161.9341 (7) 17,751 I By Longitude Capital Associates, L.P. (3)
Ordinary Shares 02/28/2014   S   8,866 D $ 160.7636 (8) 876,777 I By Longitude Venture Partners, L.P. (3)
Ordinary Shares 02/28/2014   S   180 D $ 160.7731 (9) 17,571 I By Longitude Capital Associates, L.P. (3)
Ordinary Shares 02/28/2014   S   20,977 D $ 159.9108 (10) 855,800 I By Longitude Venture Partners, L.P. (3)
Ordinary Shares 02/28/2014   S   423 D $ 159.9091 (11) 17,148 I By Longitude Capital Associates, L.P. (3)
Ordinary Shares 02/28/2014   S   28,070 D $ 159.0284 (12) 827,730 I By Longitude Venture Partners, L.P. (3)
Ordinary Shares 02/28/2014   S   559 D $ 159.0287 (13) 16,589 I By Longitude Capital Associates, L.P. (3)
Ordinary Shares 02/28/2014   S   435,588 D $ 150.5 392,142 I By Longitude Venture Partners, L.P. (3)
Ordinary Shares 02/28/2014   S   8,731 D $ 150.5 7,858 I By Longitude Capital Associates, L.P. (3)
Ordinary Shares 03/03/2014   S   300 (2) D $ 147.8667 (14) 11,461 (2) I By Longitude Capital Partners, LLC (3)
Ordinary Shares 03/03/2014   S   2,700 D $ 148.5511 (15) 8,761 I By Longitude Capital Partners, LLC (3)
Ordinary Shares 03/03/2014   S   3,700 D $ 149.4203 (16) 5,061 I By Longitude Capital Partners, LLC (3)
Ordinary Shares 03/03/2014   S   1,166 D $ 150.4536 (17) 3,895 I By Longitude Capital Partners, LLC (3)
Ordinary Shares 03/03/2014   S   3,895 D $ 153.7979 (18) 0 I By Longitude Capital Partners, LLC (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (right to buy) $ 4 02/28/2014   X     929,243 07/07/2009 07/06/2016 Ordinary Shares 929,243 $ 0 0 I By Longitude Venture Partners, L.P. (3)
Warrant (right to buy) $ 4 02/28/2014   X     18,624 07/07/2009 07/06/2016 Ordinary Shares 18,624 $ 0 0 I By Longitude Capital Associates, L.P. (3)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
ENRIGHT PATRICK G
C/O LONGITUDE CAPITAL PARTNERS, LLC
800 EL CAMINO REAL, SUITE 220
MENLO PARK, CA 94025		   X      

Signatures

 /s/ Patrick G. Enright   03/04/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Reflects acquisition of ordinary shares upon exercise of in-the-money warrant and is therefore exempt from the operation of Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-6(b).
(2) On February 28, 2014, Longitude Ventures Partners, L.P.("LVP") and Longitude Capital Associates, L.P.("LCA") distributed to their partners all of the ordinary shares of which they were the record holder prior to the exercise of warrants reflected in this report, totaling 768,670 ordinary shares held of record by LVP and 15,422 shares held of record by LCA. The reporting person reported beneficial ownership over all such shares in his prior reports filed under Section 16(a) of the Securities Exchange Act of 1934, as amended(the "Exchange Act"). The general partner of each of LVP and LCA, Longitude Capital Partners, LLC("LCP"), received an aggregate of 11,761 ordinary shares in such distributions, consisting of 11,530 ordinary shares from LVP and 231 ordinary shares from LCA.
(3) The reporting person disclaims beneficial ownership of the securities of Jazz Pharmaceuticals plc held of record by LVP, LCA and LCP, except to the extent of his pecuniary interest therein.
(4) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $163.48 to $162.50. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(5) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $163.48 to $162.50. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(6) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $162.43 to $161.45. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(7) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $162.43 to $161.45. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(8) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $161.37 to $160.41. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(9) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $161.37 to $160.41. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(10) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $160.25 to $159.26. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(11) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $160.25 to $159.26. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(12) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $159.24 to $159. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(13) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $159.24 to $159. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(14) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.82 to $147.90. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(15) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.02 to $148.905. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(16) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.95 to $149.91. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(17) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.99 to $150.98. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.
(18) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.535 to $154.055. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Jazz Pharmaceuticals plc or a security holder of Jazz Pharmaceuticals plc full information regarding the number of shares and prices at which the sales were effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.